No coin nor oath required. For personal study only.
Darucainide (B) is a new, orally available class IBagent and was shown to be highly effective in experimental arrhythmias. We initially studied 12 pts (group A: 40-68 years, 6 men) with very frequent, repetitive and refractory (< 2 agents) ventricular premature beats (5600 VPB/h, median: 18.552 VPDs/24h) by iv B 80 mg/h for 1-7 hours. When VPB were reduced to >90% during two 30 min intervals (responders, R), infusion was continued for 24h with l-36mg/h (calculated by a newly designed pharmacokinetic model). Holter (H) was recorded prior to B (48h), during dose titration, 24h-infusion and washout period (24h). After a mean of 185 mg B iv, 9/12 pts were R. VPB suppression >84%(mean: -73~) persisted in 6/gpts for 24h (mean dose: ISmg/h). Complex VPBs were reduced by -96~. In 5 pts VPB suppression persisted for >Ii hours after H withdrawn. Adverse events (2 pts with heat sensations) were minor. In conclusion, B is a new, effective class IB agent with a very long half-life; significant plasma level and antiarrhythmic efficacy persists for >16h after i.v. withdrawn.
π SIMILAR VOLUMES
Electrophysiologic techniques are used to assess the properties of antiarrhythmic drugs and also to provide support for the selection of antiarrhythmic therapy for individual patients. Assessment of the antiarrhythmic efficacy of drugs requires that the arrhythmia can be induced by programmed electr
It is important to consider the hemodynamic effects of antiarrhythmic drugs, because the majority of patients who require these drugs already have compromised cardiac function. The presently available antiarrhythmic agents vary in their potential for producing negative inotropic effects on the myoca